Rationale: 1994, selected patients(pts) early stage IIIA-NSCLC (operable, 1-2 LN involved at mediastinoscopy, no clinical N2, no bulky/extranodal disease) were taken to upfront surgery(S) at centers in Europe/North America. We compared this approach to aggressive tri-modality therapy -induction chemotherapy(CTx), preoperative radiochemotherapy(RTx/CTx) and definitive S -in a multicenter randomized GERMAN KREBSHILFE trial (full trials grant). ; med event-free surv: 9 mo vs 15 mo (p = 0.12 W); med disease specific(spec) surv 10 mo vs 18 mo ( p = 0.026 W). 5-year overall surv 18% vs 16%; event-free surv: 20% vs 24%; disease spec surv 23% vs 24%. Beyond 3 yrs from randomization intercurrent events (co-morbidities) and second cancers predominant reason for deaths. Med surv of pts still alive 3/07: 94 mo(n = 14,73+-149+). Conclusion: This tri-modality protocol was feasible/safe in the multicenter setting. S following complex bi-modality induction did not show increased morbidity/mortality. Strong trend towards lung-sparing surgery in the arm with preoperative complex induction (down-staging? organ-sparing effect?). Results of this trial mandate rate of less extensive S interventions (eg. lobectomies) as further important endpoint to be added within clinical trials of comparable pts populations (significant risk for pneumonectomy at thoracotomy). Although surv data favoured tri-modality in the first four yrs -overall no of pts randomized does not allow valid conclusions concerning this endpoint. Currently, data on brain-relapse -free surv are analyzed with different policy for PCI in both arms (PCI vs no PCI).
Dept. of Nuclear Medicine University Hospital Gasthuisberg and Leuven Lung Cancer Group, Leuven, Belgium Background: Surgical resection in patients with stage IIIA-pN2 NSCLC is usually reserved for patients with downstaging of mediastinal lymph nodes (LNs) after induction therapy. However, clinical restaging after induction therapy is often inaccurate. Moreover, there are insufficient data to exclude all patients with persistent mediastinal disease from surgery. Assuming baseline endoscopic mediastinal staging in the near future, we explored a restaging strategy combining tissue analysis of mediastinal LNs obtained post-induction, and FDG-PET for monitoring response in the primary tumour. Methods: Baseline and repeat PET after three cycles of induction chemotherapy, as well as complete resection specimens of both mediastinal LNs and primary tumour, were available in 30 patients out of our prospective database of surgical multimodality therapy in IIIA-pN2 NSCLC patients (period: 04-1995 to 06-2002 ref. Lorent et al, Ann Oncol 15:1645 , 2004 . In these 30 patients, histological tumour grading of both LNs and primary tumour was performed by means of conventional morphometric procedures based on a point counting technique, as described by Gundersen (ref. Gundersen et al, APMIS 96:379, 1988) . Three morphometric grading groups were considered: mediastinal downstaging (clearance of mediastinal disease), 'minor' residual mediastinal disease (<10% viable tumour cells) and 'major' residual mediastinal disease (>10% viable tumour cells). These mediastinal morphometric grading groups, together with the percent decrease of SUVmax of the primary tumour, were correlated with survival to establish an algorithm for prognostic restaging. Results: The median and 5-year overall survival for the 30 patients was 36.4 months and 30%, respectively. The median decrease of SUVmax on the primary tumour between baseline and repeat PET scan was 60%, and this value was used as cut-off. A >60% decrease compared to a <60% decrease of SUVmax resulted in a median survival time of 57.5 versus 18.3 months and 5-year overall survival 47% versus 13%, respectively; log-rank p=0.01, HR 0.34 (95%CI 0.12-0.74). No patient with 'major' residual mediastinal disease survived 5 years, while 5-year overall survival was 43% both in patients with mediastinal clearance as well as in those with 'minor' residual mediastinal disease. Combined prognostic stratification resulted in two subgroups: patients with downstaging or persistent 'minor' mediastinal LN involvement and >60% decrease of SUVmax on the primary tumour were allocated as 'Good Prognosis group' (n=13). Patients with downstaging or persistent 'minor' mediastinal LN involvement and <60% decrease of SUVmax on the primary tumour were pooled with patients having persistent 'major' mediastinal LN involvement and allocated as 'Poor Prognosis group' (n=17). The median and 5-year overall survival for these Good and Poor Prognosis groups were "not reached" versus 18.3 months, and 62% versus 6%, respectively; log-rank p<0.0001, HR 0.18 (95%CI 0.06-0.38).
Genetic Epidemiology Research Institute, Irvine, CA, USA
Background: The T2 descriptor in the AJCC staging for non-smallcell lung cancer (NSCLC) contains several non-size based criteria in addition to the criterion of tumor size greater than 3 cm. It remains unknown if there are survival differences between patients whose tumors were staged according to these non-size based criteria when compared to patients whose tumors were staged according to tumor size. Methods: We analyzed 10,545 stage IB NSCLC patients from the California Cancer Registry (CCR) from 1989 to 2003. These patients were staged as IB disease according to three non-overlapping main criteria: 1) tumor size [T2S]; 2) visceral pleura invasion, hilar atelectasis or obstructive pneumonitis [T2P]; 3) main bronchus involvement ≥ 2 cm from the carina [T2C]. Univariate survival analyses were conducted using the Kaplan-Meier method. Multivariate survival analyses were performed using Cox proportional hazards ratios. Results: 5385 (51.1%) IB patients were staged according to tumor size [T2S], 4557 (43.2%) patients were staged by visceral pleura invasion, hilar atelectasis or obstructive pneumonitis [T2P] and 603 (5.7%) patients were staged by main bronchus involvement ≥ 2 cm from the carina [T2C]. 35.7% of the IB patients due to visceral pleura invasion, hilar atelectasis or obstructive pneumonitis [T2P] and 29.7% of the patients due to main bronchus involvement ≥ 2 cm from the carina [T2C] had tumors 3 cm or smaller. There was statistical significant difference in the 5-year survivorship and median overall survival (OS) among the 3 types of stage IB NSCLC patients: (T2C: 38.6% and 39 months; T2P: 38.0% and 38 months; T2C: 40.3% and 39 months; P = 0.0031). The 5-year survival and median OS of these IB patients with tumor 3 cm or smaller were 53.3% and 67 months for T2P and 52.6% and 73 months for T2C respectively, similar to the 53.2% 5-year survival and 67 months of median OS for stage IA patients. Cox proportional hazards model revealed that T2P > 3 cm is a poor prognostic factor (vs. T2S, Hazard Ratio [HR] = 1.13, 95% Confidence Interval (CI) = 1.06-1.20) while T2P ≤ 3 cm was a favorable prognostic factor (vs. T2S, HR = 0.87, 95% CI = 0.80-0.95). T2C > 3 cm (vs. T2S, HR = 0.98, 95% CI = 0.84-1.13) and T2C ≤ 3 cm (vs. T2S, HR = 0.86, 95% CI = 0.69-1.08) were not independent poor prognostic factors. Conclusions: Non-size based T2 descriptors-visceral pleura invasion, hilar atelectasis or obstructive pneumonitis are poor independent prognostic factors when the tumor size was greater than 3 cm. Stage IB NSCLC patients staged by non-size based criteria T2 descriptors whose tumors were 3 cm or smaller had survival similar to stage IA NSCLC patients. Future proposed changes to the AJCC T2 descriptor, the non-size based criteria should be linked to size criteria rather than as independent criteria. The prognostic significance of the T2C criterion requries further studies. Cox proportional hazards model showing prognostic significance of various AJCC T2 descrpitors.
T2 descriptor
Number Background: Treatment and prognosis of patients with non-small cell lung cancer depend on the stage of the disease at the time of the diagnosis. Mediastinoscopy has been the golden standard for staging of the mediastinum for many years, and it has been proven that the false negative rate of N2-disease by this procedure is near 20% or more. The consequence of this is often a futile thoracotomy without benefit for the patient. We would like to report the results of our preliminary experience with EBUS/TBNA for staging of the mediastinum. Methods: A total of 152 consecutive patients were examined by EBUS/TBNA during the first year (2006) the method was used in our department. The indication was mediastinal staging in 82 patients (53.9%). The remaining 70 patients were examined because of an undiagnosed mediastinal mass, follow-up after resection of NSCLC, or restaging after chemotherapy. The 3 examiners had no previous experience with endoscopic ultrasound, but were trained for a period of 2 days in another institution with experience in the method. The examinations of the 82 patients were carried out in general anaesthesia with a linear scanner (BF-UC160F, Olympus). Cytological samples were taken by 22G needle aspiration (NA-201SX-4022, Olympus) from all lymph node stations visualized. Patients positive for N2 or N3-disease (n=32) by EBUS/TBNA were not examined further, but referred to oncological treatment. Patients without N2 or N3-disease
